Gisondi, P <br/><br/>
Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.  [electronic resource] 

 -  The British journal of dermatology  08 2020 
 - 397-398 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1365-2133 
<br/><br/><label>Standard No.: </label>10.1111/bjd.19013  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Biosimilar Pharmaceuticals--therapeutic use<br/>Drug Substitution<br/>Humans<br/>Infliximab--therapeutic use<br/>Psoriasis--drug therapy<br/>Treatment Outcome